Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant

被引：108

作者：

Arai, Sally ^{[1
]}

Fanale, Michelle ^{[2
]}

deVos, Sven ^{[3
]}

Engert, Andreas ^{[4
]}

Illidge, Tim ^{[5
]}

Borchmann, Peter ^{[4
]}

Younes, Anas ^{[2
]}

Morschhauser, Franck

McMillan, Alex ^{[1
]}

Horning, Sandra J. ^{[1
]}

机构：

[1] Stanford Univ, Stanford, CA 94305 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Univ Calif Los Angeles, Los Angeles, CA USA

[4] German Hodgkin Lymphoma Study Grp, Cologne, Germany

[5] Univ Manchester, Inst Canc Sci, Manchester, Lancs, England

来源：

LEUKEMIA & LYMPHOMA | 2013年 / 54卷 / 11期

关键词：

HIGH-DOSE THERAPY; PROGNOSTIC-FACTORS; DISEASE ANALYSIS; PHASE-II; CHEMOTHERAPY; MULTICENTER; TRIAL;

D O I：

10.3109/10428194.2013.798868

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2531 / 2533

页数：3

共 15 条

[1] Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: Analysis of 280 patients from the French registry [J].

Brice, P ;

Bouabdallah, R ;

Moreau, P ;

Divine, M ;

Andre, M ;

Aoudjane, M ;

Fleury, J ;

Anglaret, B ;

Baruchel, A ;

Sensebe, L ;

Colombat, P .

BONE MARROW TRANSPLANTATION, 1997, 20 (01) :21-26

[2] Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease [J].

Diehl, V ;

Franklin, J ;

Pfreundschuh, M ;

Lathan, B ;

Paulus, U ;

Hasenclever, D ;

Tesch, H ;

Herrmann, R ;

Dörken, B ;

Müller-Hermelink, H ;

Dühmke, E ;

Loeffler, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24) :2386-2395

[3] A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma [J].

Fehniger, Todd A. ;

Larson, Sarah ;

Trinkaus, Kathryn ;

Siegel, Marilyn J. ;

Cashen, Amanda F. ;

Blum, Kristie A. ;

Fenske, Timothy S. ;

Hurd, David D. ;

Goy, Andre ;

Schneider, Stephanie E. ;

Keppel, Catherine R. ;

Wagner-Johnston, Nina D. ;

Carson, Kenneth R. ;

Bartlett, Nancy L. .

BLOOD, 2011, 118 (19) :5119-5125

[4] High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices [J].

Horning, SJ ;

Chao, NJ ;

Negrin, RS ;

Hoppe, RT ;

Long, GD ;

Hu, WW ;

Wong, RM ;

Brown, BW ;

Blume, KG .

BLOOD, 1997, 89 (03) :801-813

[5] Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma:: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG) [J].

Josting, A ;

Rudolph, C ;

Mapara, M ;

Glossmann, JP ;

Sienawski, M ;

Sieber, M ;

Kirchner, HH ;

Dörken, B ;

Hossfeld, DK ;

Kisro, J ;

Metzner, B ;

Berdel, WE ;

Diehl, V ;

Engert, A .

ANNALS OF ONCOLOGY, 2005, 16 (01) :116-123

[6] New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group [J].

Josting, A ;

Franklin, J ;

May, M ;

Koch, P ;

Beykirch, MK ;

Heinz, J ;

Rudolph, C ;

Diehl, V ;

Engert, A .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :221-230

[7] Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma [J].

Josting, Andreas ;

Mueller, Horst ;

Borchmann, Peter ;

Baars, Joke W. ;

Metzner, Bernd ;

Doehner, Hartmut ;

Aurer, Igor ;

Smardova, Lenka ;

Fischer, Thomas ;

Niederwieser, Dietger ;

Schaefer-Eckart, Kerstin ;

Schmitz, Norbert ;

Sureda, Anna ;

Glossmann, Jan ;

Diehl, Volker ;

DeJong, Daphne ;

Hansmann, Martin-Leo ;

Raemaekers, John ;

Engert, Andreas .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (34) :5074-5080

[8] A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma [J].

Leemhuis, T ;

Wells, S ;

Scheffold, C ;

Edinger, M ;

Negrin, RS .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (03) :181-187

[9] Risk-Adapted Salvage Treatment With Single or Tandem Autologous Stem-Cell Transplantation for First Relapse/Refractory Hodgkin's Lymphoma: Results of the Prospective Multicenter H96 Trial by the GELA/SFGM Study Group [J].

Morschhauser, Franck ;

Brice, Pauline ;

Ferme, Christophe ;

Divine, Marine ;

Salles, Gilles ;

Bouabdallah, Reda ;

Sebban, Catherine ;

Voillat, Laurent ;

Casasnovas, Olivier ;

Stamatoullas, Aspasia ;

Bouabdallah, Krimo ;

Andre, Marc ;

Jais, Jean-Philippe ;

Cazals-Hatem, Dominique ;

Gisselbrecht, Christian .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (36) :5980-5987

[10] A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model [J].

Moskowitz, CH ;

Nimer, SD ;

Zelenetz, AD ;

Trippett, T ;

Hedrick, EE ;

Filippa, D ;

Louie, D ;

Gonzales, M ;

Walits, J ;

Coady-Lyons, N ;

Qin, J ;

Frank, R ;

Bertino, JR ;

Coy, A ;

Noy, A ;

O'Brien, JP ;

Straus, D ;

Portlock, CS ;

Yahalom, J .

BLOOD, 2001, 97 (03) :616-623

← 1 2 →